CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...

Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment ...

Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.

HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under ...

CNS Pharmaceuticals is currently developing a portfolio of anti-cancer drugs, with its lead candidate, Berubicin, being an innovative anthracycline believed to be the first of its kind to cross ...

CNS Pharmaceuticals is currently developing a portfolio of anti-cancer drugs, with its lead candidate, Berubicin, being an innovative anthracycline believed to be the first of its kind to cross the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...